Rituximab in the treatment of pembrolizumab-induced myasthenia gravis by Crusz, S.M., Radunovic, A., Shepherd, S., Shah, S., Newey, V., Phillips, M., Lim, L., Powles, T., Szlosarek, P.W., Shamash, J., Rashid, S.

Get full text

222 MesobanK – a UK based bioresource for malignant mesothelioma by Rintoul, R.C, Rassl, D.M, Maskell, N, Gittins, J, Szlosarek, P.W, Kerr, K.M, Booton, R, Hughes, V, Fennell, D.A, Marciniak, S.J

Get full text

50 Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience by Lewis, A, Hough, N, Woolf, D.K, Trehy, R, Kolotia, B, Reeves, A, Szlosarek, P.W, Wells, P, Steele, J

Get full text

188 Three years experience of chemotherapy for small cell lung cancer at a tertiary referral centre by Hough, N, Lewis, A, Woolf, D.K, Trehy, R, Kolotia, B, Reeves, A, Szlosarek, P.W, Wells, P, Steele, J

Get full text

221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma by Szlosarek, P.W., Fennell, D.A., Rudd, R.M., Lind, M., Ranson, M., Hackshaw, A., Bomalaski, J.S., Steele, J.P.C.

Get full text